ArticleVaccine2025
New adult and adolescent tuberculosis vaccines and Indonesia: policy planning and evidence, November 2024.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Childhood immunization barriers and interventions in low- and middle-income countries: A scoping review of access, delivery systems, and health literacy.Human vaccines & immunotherapeutics · 2026Article
- Determinants of stunting among Indonesian children: a cross-sectional study on the role of child, maternal, and vaccination factors.BMC pregnancy and childbirth · 2026Article
- How can new TB vaccines be effectively introduced in Indonesia? Insights from diverse stakeholders.PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
This report summarizes the proceedings of a policy and planning meeting convened in Indonesia, by the Ministry of Health and the World Health Organization, on potential new tuberculosis (TB) vaccines intended for adults and adolescents. Given that Indonesia bears the second highest TB burden globally, and that it is participating in the phase III efficacy study for one of the leading vaccine candidates that could be approved for use by 2028, the meeting aimed to discuss strategies and evidence needs that could accelerate vaccine introduction. The meeting, held in November 2024, was attended by Indonesian policymakers, researchers, health advocates and community representatives, alongside observers from immunization and TB programmes working at the global level, as well as donors. This report offers several key recommendations to ensure new TB vaccines for adults and adolescents are available, accessible and acceptable in Indonesia, as soon as possible after regulatory approval. The vaccine implementation strategy is expected to be through a stratified, geographical approach, initiating in provinces with the highest disease and socio-economic burden. As such, improved data on disease, infection prevalence and acceptability within different age cohorts and populations are needed to inform national and sub-national (e.g., province or district level) health and economic impact modelling. Early studies on knowledge, attitudes and practices of new TB vaccines for adults and adolescents will help to engage community leaders and advocates and ensure effective, culturally acceptable communication to improve acceptability. Of greatest urgency, a national strategic plan for new TB vaccine introduction, including a roadmap of critical activities, responsible entities and a stakeholder engagement plan are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.